🔎︎
A living systematic review presented at the 2026 AAN Annual Meeting offered managed care audiences a comprehensive look at where glucagon-like peptide-1 (GLP-1) receptor agonists stand in Alzheimer's disease (AD), a question with direct implications for formulary stewardship as GLP-1 prescribing volumes continue to expand across payer books of business.
Researchers integrated phase 2/3 trials and large real-world studies conducted between 2000 and 2025, evaluating GLP-1 receptor agonists to assess clinical efficacy, biomarker outcomes, safety, and accessibility in AD. The analysis included liraglutide, semaglutide, and exenatide, then applied an Efficacy-Feasibility Matrix to assess translational readiness for scalable use.
The real-world signal was notable: comparative studies in more than 2 million individuals with diabetes associated GLP-1 receptor agonists with roughly 20% to 35% lower dementia incidence versus DPP-4 or SGLT2 inhibitors, with the strongest association seen for semaglutide. However, those findings did not translate to the clinic. The phase 3 EVOKE and EVOKE+ trials of oral semaglutide in early AD found no significant difference from placebo on cognitive or functional outcomes at two years, though CSF biomarkers of tau pathology and neuroinflammation shifted modestly in a favorable direction.
The review's feasibility analysis flagged cost and the injectable delivery of some agents as barriers to broader use. Semaglutide's oral formulation may offer advantages for clinical application, particularly due to its potential for greater scalability.
For payers, the takeaway is nuanced. GLP-1 agents prescribed for diabetes or obesity may carry an incidental neuroprotective signal at the population level, but phase 3 evidence does not yet support an AD indication. Plans managing prior authorization policies for these agents should monitor ongoing trial readouts, particularly in pre-symptomatic populations where the biomarker data may be more actionable.
